News

Most development in artificial intelligence (AI) happens inside data centers, which are filled with thousands of purpose-designed chips from suppliers like Nvidia, Advanced Micro Devices, and

Viking Therapeutics (NASDAQ: VKTX) has intrigued investors over the past year and a half because it's involved in a potential David and Goliath story. Today, pharma giants Eli Lilly and Novo Nordisk

There is no sugarcoating it: Vertex Pharmaceuticals (NASDAQ: VRTX) has faced significant issues this year that have sunk its stock price. The company's shares are down 2% year-to-date, while the S&P

The biotech industry can be highly volatile. Companies in the sector can sometimes see their shares double in a short period due to hitting important clinical milestones. Over a more extended

Investing on a budget can still be lucrative. And even though the best stocks tend to attract plenty of attention from investors who bid up their share prices, it's possible to find quality

Medical device and diagnostics company Bruker (NASDAQ: BRKR) wasn't looking like the cure for any investor's ailments on Wednesday. The stock was hit with an assertive sell-off from the market

There are a number of reasons to believe that Pfizer (NYSE: PFE) is an attractive dividend stock. The lofty 6.9% dividend yield is the obvious first reason, but the healthcare giant also has a long

The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching

HealthEquity (NASDAQ:HQY), a leading provider of Health Savings Account (HSA) custodial services in the United States, reported fiscal 2026 second-quarter earnings on Sept. 2. The release noted

UnitedHealth Group (NYSE: UNH) has attracted much attention over the past year, for both good and bad reasons. Recently, well-known value investors Warren Buffett of Berkshire Hathaway and Michael

A buoyant stock market that keeps reaching new heights is great for the stocks already in our brokerage accounts. After a few strongly positive years, though, finding stocks that pay high dividend

Pfizer (NYSE: PFE) has become the dividend investor's siren song. With shares down 31% over the past five years and a current yield of 7%, the pharmaceutical giant offers one of the juiciest payouts

Some decisions require lengthy deliberations and extensive analysis. Others don't.

Three Fool.com contributors think they've identified pharmaceutical stocks in the latter category. Here's why they

Dividend stocks are a great way for investors to generate passive income that can be more reliable and predictable than investing in stocks for pure appreciation. While there are no guarantees in

Over the past several weeks, investors have been bombarded with a wave of updates as companies reported earnings results for the second calendar quarter. For technology investors, artificial

One of the highest honors among dividend stocks is to be a Dividend Aristocrat®, which requires 25 consecutive years or more in annual increases. The title Dividend Aristocrat is such a big deal

Dividend Champions are long-term winners. These companies have grown their dividends for at least 25 straight years. They don't have to be members of the S&P 500 (SNPINDEX: ^GSPC), which broadens

Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as

If you're looking for growth stocks that could make dramatic gains in a short amount of time, the healthcare sector has you covered. Recently, investment bank analysts have been pounding the table

Numerous companies in the healthcare sector are feverishly busy developing obesity drugs, as these products have taken the medical world by storm. One of the more prominent developers

Nvidia (NASDAQ: NVDA) closed at $180.12, down 0.82%. Trading volume surged to 278 million shares, well above the 178 million three-month average. The chipmaker, valued at $4.4 trillion, traded as